Within the TME, the dynamic interaction between tumour cells, immune cells and stromal components influences the efficacy of immunotherapies, such as PD‐1/PD‐L1 inhibitors, that have revolutionized the treatment landscape for LUAD.7, 8. The gene discussed is CD274; the disease is neoplasm.